The Head, PMed -ImmunoOncology and Disease Strategy is accountable for all Precision Medicine strategies to support assets in the Immuno-Oncology portfolio. This role has multiple strategically important aspects that require the incumbent to provide strong cross-functional and leadership across diverse stakeholders comprising Senior Leadership in Discovery and Development Therapeutic Areas, Global Commercial Development and Global Medical Affairs.
First the incumbent is expected to provide a clear vision for the translational discovery and development of clinical biomarkers with validation in clinical studies across the immune-oncology portfolio. The impact of these strategies is expected to inform dose selection through development of robust PD and mechanistic insights in translational models and patients. Additionally, the identification of predictive markers and clinical validation is expected to strongly influence clinical development strategy and interpretation of data from clinical studies through prospective analysis of predictive hypotheses. These clinical insights, taken together with translation research and disease strategy data, should inform on proof of mechanism, identify opportunities for combination studies and direct enrolment of patient populations that are predicted to respond to Abbvie Immuno-Oncology clinical candidates, ranging from selection of tumor types to specific molecularly defined patient sub-populations.
Additionally, the incumbent is expected to create a vision and guide execution of overarching disease strategy framework to guide teams in Development and Discovery stages to identify key disease opportunities and or patient segments that are driven by mechanisms that are currently being explored in the internal Immuno-Oncology portfolio, can be addressed with novel combinations or may be accessed through BD partnerships with external companies. This framework is expected to leverage or generate comprehensive molecular data that are highly annotated with clinical phenotypes from internal samples/datasets and/or from external partnerships. The development of this framework and the associated disease strategies that it informs will require the incumbent to leverage resources in her/his team, as well as cross-functionally, to align the goals of these strategies with teams in the Abbvie Immuno-Oncology portfolio. This work should also include the development and clinical validation of molecular markers that may serve as surrogate endpoints. Given the anticipated broad reaching impact of these strategies the incumbent is expected to create strong aligned partnerships with colleagues in clinical development, global medical affairs and Discovery as well as with advanced analytics groups across Abbvie.
Given the importance of Data Sciences and clinco-genomic data, the incumbent is expected to provide strong partnership with the Convergence Digital Platform to ensure that its success in addressing PMed Assets and Disease Strategic needs across Immuno-Oncology.
The successful candidate will enjoy broad support for his/her vision at Abbvie. To empower this role, the incumbent will serve as a contributor at Development Review Committee, Research Review Committees when Immuno-Oncology assets are discussed.
This is an unprecedented opportunity to provide leadership for Precision Medicine programs and Disease Strategies across the Abbvie pipeline, focused on an industry leading Immuno-Oncology Oncology portfolio
- MD/PHD or PHD with extensive experience working in the application of precidine medicine and translational biology approaches to inform clinical development.
- The incumbent should have an excellent publication record generated from at least 10 years in academia and or in an Biopharma setting.
- It is expected that the incumbent is recognized across the field as a thought leader in the area of Immuno-Oncology , ideally leveraging clinco-genomic data and approaches to solve clinical stage needs/questions.
AbbVie is an equal opportunity employer including disability/vets. It is AbbVie’s policy to employ qualified persons of the greatest ability without discrimination against any employee or applicant for employment because of race, color, religion, national origin, age, sex (including pregnancy), physical or mental disability, medical condition, genetic information, gender identity or expression, sexual orientation, marital status, status as a disabled veteran, recently separated veteran, Armed Forces service medal veteran or active duty wartime or campaign badge veteran or a person’s relationship or association with a protected veteran, including spouses and other family members, or any other protected group status. We will take affirmative action to employ and advance in employment qualified minorities, women, individuals with a disability, disabled veterans, recently separated veterans, Armed Forces service medal veterans or active-duty wartime or campaign badge veterans. The Affirmative Action Plan is available for viewing in the Human Resources office during regular business hours.